Irish Nationwide manager shocked at Michael Fingleton's ‘get out of jail card' for borrower
Conal Regan, who joined the bank after Mr Fingleton left the society in April 2009, told the High Court on Wednesday that the defendant allegedly wrote a letter to a lender, Louis Scully, who borrowed almost €6 million to purchase land in Co Meath in October 2007, confirming that the sum loaned to him was a 'non-recourse' one.
A non-recourse loan means that debt on a loan is secured by the collateral and cannot be pursued by the lender from the borrower.
The High Court civil case, which is in its third week, against the former INBS chief executive and managing director alleges he negligently mismanaged the building society and engaged in property 'gambles' with high-net-worth individuals in an informal and speculative manner in the mid-2000s, leading to fatal losses.
READ MORE
Mr Fingleton (87), who cannot give evidence due to ill-health, joined the building lender in 1971 and retired in 2009. He held the roles of both managing director and chief executive in that time. At its height in 2007, INBS had reported assets of €16 billion but was a high-profile casualty of the financial crisis in 2008.
Liquidators for Irish Banking Resolution Corporation (IBRC) have taken the case against Mr Fingleton, who denies the allegation of negligent mismanagement.
The total losses at INBS had been estimated to be €6 billion. However, only €290 million in damages is being pursued by IBRC, relating to five specific loans, allegedly approved by Mr Fingleton.
The court has been told that Mr Fingleton was allegedly 'nodding through' top-ups and extensions to certain clients without the knowledge of the society's board.
At the High Court on Wednesday, former INBS manager Mr Regan, who joined the society in late October 2009, said he was dealing with 'significantly' distressed credits at the lender.
When Mr Regan queried and tested loans issued to Mr Scully, he was told by letter from Mr Scully that the money advanced to him were all 'non-recourse' loans.
Lyndon MacCann SC, for IBRC's liquidators, was told by Mr Regan that a February 2009 letter from Mr Scully to Tom McMenamin, then manager of commercial lending at Nationwide, referred to a list of borrowings by Mr Scully and other individuals that stated 'nobody was getting any younger'. Mr McMenamin wrote back saying that all loans to Mr Scully were made on a non-recourse basis.
Mr Regan said he could not find any reference 'anywhere' in the paperwork about a non-recourse element in a loan to Mr Scully for Meath lands – measured at 21,700 acres – at €598,7850, arising from a value of €275,000 per acre, which Mr Regan said 'seems exceptional, very, very high'.
Mr Regan said he reacted by thinking 'why in the name of god was a get-out-of-jail card given here, given the level of funding that had been provided?'
'I just could not understand that somebody could possibly believe that letter would trump agreements or legal documents signed and on a 'normal-recourse' basis. All of a sudden there is this and it just didn't make sense,' Mr Regan told the court.
Mr Regan said he had looked at the files regarding Mr Scully's loans and that 'non-recourse was mentioned nowhere. Nowhere'.
Mr Regan told the court he asked Mr McMenamin 'why in the name of god' was the letter of confirmation issued and claimed Mr McMenamin told him: 'I was only doing what the boss told me to do'.
Mr MacCann asked who was being referred to as 'the boss' to which Mr Regan said he was told by Mr McMenamin that this was a reference to Mr Fingleton Sr.
Later in December Mr Scully wrote to Mr Regan saying as far as he was concerned all of his business with the society was on an non-recourse basis and that this had been agreed by Mr Fingleton.
Mr Regan told Mr Justice Michael Quinn that it was a 'shocking assertion' and that 'individuals were not even putting hands in their pockets' if they had a 'free bet' on getting planning or zoning for lands.
'It was a get out of jail card. It was incredible. I have never, never come across it before,' said Mr Regan.
In response to a request for any documentary evidence as to the agreement between Mr Scully and Mr Fingleton, Mr Scully wrote back on March 25th, 2010, enclosing a letter of confirmation of the non-recourse loans from Mr Fingleton and writes 'I trust this brings matters to a conclusion'.
Mr Regan said he was left 'absolutely shocked' by the letter from Mr Fingleton.
The case continues at the High Court.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Irish Times
4 hours ago
- Irish Times
Gareth Sheridan: Nutriband ‘will help a lot of people who are dealing with addiction and people who are dealing with pain'
Nutriband is a pharmaceutical company that was founded in Dublin in 2012 before relocating to Florida in 2016. Gareth Sheridan, who recently announced his intention to run for president and has stepped aside for three months as chief executive, is its founder. The company's lead product is Aversa, which it describes as 'abuse-deterrent transdermal technology', which incorporates aversive agents to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential, specifically opioids. Its first application is its abuse-deterrent fentanyl transdermal patch, which it is developing to provide clinicians and patients with extended-release chronic pain relief. It is awaiting regulatory clearance for this product in the US. The company has operations in Florida, Georgia, and North Carolina, and recently began its expansion back to Dublin. READ MORE What lightbulb moment prompted you to start-up in business? It was originally a thesis idea. I had noticed a patch that my dad wears and began wondering what other types of medications could be delivered that way that had not been explored yet. The thesis became a business plan, and Nutriband was registered in 2012. Describe your business model and what makes your business unique. We structured the company in a unique way, using capital markets and a public listing approach. We listed on the OTC Markets in 2016 and started using stock to purchase companies and technologies in place of cash. This helped us to avoid raising expensive early capital and retain a major equity stake in the company today, even after an eventual qualification to list on the Nasdaq (in New York) in 2010. We also do not develop new drug applications. We take existing generic medications and use our technologies to improve upon those and relaunch them as a branded product again. What is your greatest business achievement to date? Growing the company to a level where we qualified to list on the Nasdaq Stock Exchange and getting to ring the opening bell. What was your back-to-the-wall moment and how did you overcome it? We almost got sued by the SEC (The US Securities and Exchange Commission) for an accidental erroneous disclosure in one of our filings while on the OTC markets. At first, we thought it could be explained. However, it grew to the point where they were doubling down. We hired an excellent attorney with SEC experience and eventually settled the issue in a cease-and-desist, no-admit, no-deny agreement. This led to our back-to-the-wall moment, where, while running on fumes financially, we received a rejection from Nasdaq in our first application. After a couple of days of self-pity, we got back to work, raised some working capital with existing shareholders, and grew the company's equity by $7.5 million (€6.4 million) over the course of the next year. We reapplied to list again successfully. What moment would you cite as a turning point for the company? Credibility provided by our Nasdaq listing and subsequent partnership with Kindeva Drug Delivery (formerly 3M Drug Delivery), where Kindeva supplied their generic approved fentanyl patch for us to add our technology to. What were the best and the worst pieces of advice you received when starting out? The worst advice was that banks and institutions have your company's best interests at heart. I firmly believe that today, Wall Street is built on companies failing, not succeeding. Describe your growth funding path. We were reluctant to raise expensive capital early on and instead listed the company to use stock as an acquisition currency to grow. Our gamble on this paid off, and although we raised modest cash along the way, we were able to build Nutriband without any significant seed or angel rounds. We reached a market capitalisation of $120 million (its market value currently is about $75 million), and we have been able to maintain stable and steady control as a result of the minimal capital rounds. We turn down anywhere from $5 million to $15 million on a weekly basis from funds and institutions because we do not need it. We are not in the business of raising money, and having as little dilution as possible is a core focus for us as a company. How will your market look in three years and where would you like your business to be? For our first product, we are expected to reach annual revenues of $200 million. Our second product is independently estimated to have upwards of $135 million in yearly revenue. We are targeting the billion dollar club before the end of 2027. What are your annual revenues and profits? We are not yet profitable, as is typical with clinical development-stage companies. However, we also contract manufacture sports tapes and products for brands such as Reebok and KT Tape. Our target revenue from this source for the financial year to the end of January 2026 is $3 million * . This goes towards operational costs and reduces our clinical burn. Why have you decided to seek a nomination for the presidency? It's never been a more important or relevant time in our history for a young president, particularly with the average age just under 40. I would be hoping that having a younger president would help narrow the division we're seeing in the country at the moment and that we can work together to tackle the issues, particularly the housing crisis. The younger generation aren't feeling very enthusiastic that their voices are being heard. What impact will this move have on your business? The company is in very safe hands and the biggest asset at the company is the team. We've got a very definite plan and timeline between now and Christmas on what needs to be achieved. Whether I'm in there or not that timeline needs to be adhered to. The company is motoring along fine. Stepping aside is not something that I think will fundamentally affect the opportunity for the company. What happens if you win? There are mechanisms where I can put the shares into a trust. I would be very proud that it was a company that I started and be very keen to still follow the journey, just not as CEO. Nutriband as a whole is going to do a lot of will help a lot of people who are dealing with addiction and people who are dealing with pain. *An earlier version of this article stated a higher target figure for contract manufacturing, which has since been revised by the company.
Irish Times
4 hours ago
- Irish Times
‘We await with interest': Family of Sophie Toscan du Plantier supportive of fresh DNA tests in murder inquiry
The family of murdered Sophie Toscan du Plantier say they will accept whatever findings Irish forensic scientists make on foot of a series of new DNA tests on exhibits from the near 30-year-old investigation . Ms Toscan du Plantier's uncle, Jean Pierre Gazeau, said the family fully supports the decision by the Garda Serious Crime Review Team and Forensic Science Ireland (FSI) to engage US DNA collection experts irrespective of what the move yields. Mr Gazeau said he was interested to see that the Garda and FSI had decided to avail of technology provided by M-Vac Systems to examine exhibits including the stone and concrete block used to murder his niece in west Cork in 1996. 'I think it is the last chance for the Garda – unless, of course, some witness comes forward with new evidence. But even then, they may retract their story, which has happened before, but DNA evidence is objective and scientific and definitive, so it is a welcome development,' he said. READ MORE Mr Gazeau, president of the Association for the Truth about the Murder of Sophie Toscan du Plantier, said he did not want to speculate, but that the latest approach could produce a number of different scenarios. 'They may find nothing but obviously if they find DNA and it does not match that of Ian Bailey , then it has the ability to clear Bailey of any culpability,' he said. 'But even if it means the outcome is not what we expect ... it is a scientific outcome, and we must respect that finding and accept it because DNA testing is very definitive. We await with interest to hear from the Garda on what the scientists find.' Ian Bailey, the chief suspect for the murder of Sophie Toscan du Plantier, died last year aged 66. Photograph: Courts Collins Mr Bailey, an English journalist, was twice arrested in connection with the French film producer's murder, but was never charged, and repeatedly protested his innocence before his death last year at the age of 66 . He was convicted in his absence at a trial in Paris in 2019 of the voluntary homicide of Ms Toscan du Plantier and sentenced to 25 years in jail. However, attempts by French authorities to have him extradited to serve the sentence were shot down by the Irish courts . M-Vac Systems chief executive Jared Bradley and a scientist from the firm travelled to Dublin last month with their equipment and spent a week examining various exhibits gathered during the original Garda investigation into Ms Toscan du Plantier's murder. The 39-year-old's badly beaten body was found on the laneway leading to her isolated holiday home in Toormore near Schull on the morning of December 23rd, 1996. A postmortem revealed she had been bludgeoned to death with a rock and a concrete block. As well as the cavity block and rock, gardaí from the cold case review team based in Bantry brought several exhibits to the FSI laboratory for examination by the M-Vac team including Ms Toscan du Plantier's dressing gown, leggings, vest and boots. Investigators are hoping that any DNA evidence obtained will enable FSI scientists to make comparisons with DNA samples taken during the original Garda investigation from about 10 people, including Mr Bailey, identified as suspects at the time.
Irish Times
10 hours ago
- Irish Times
The Irish Times view on Budget 2026: put the focus on what is important
Over the next couple of weeks, as the Autumn political season starts to kick in, debate on October's budget will get underway in earnest. As ever, there will be a cacophony of demands from interest groups and lobbyists, looking for more spending or lower taxes for their particular cause. The job of the Government, of course, is to look through the noise to what is important. Despite the generous amount of €9.4 billion set aside for budget measures, this will not be easy. Money will be quickly eaten up through spending pressures in providing State services. Plans to hike vital investment expenditure need to be allowed for. And the demands on the table already would take up the €1.5 billion set aside for tax reductions a few times over. Yet while the choices will be sharp in some areas, context is needed. This is not shaping up to be a 'tough' budget. The promised package is still nearly three times the size of the last pre-Covid budget in 2019. The first job of the Government, indeed, is to start returning annual budgets to more sustainable levels, reducing them from the huge spending rises required during Covid-19 and to tackle the cost-of-living crisis. Claims that households are still squeezed need to be met in two ways. One is by appropriate increases in welfare and other support packages. The other is by continuing to improve the provision of services in areas such as health, education and childcare. These are much more effective in the longer-term than another round of universal cash supports. But by engaging in a blatant pre-election manoeuvre last year to repeat these 'once-off' supports again, Ministers have created a rod for their own back this time around. READ MORE Statements from Ministers that there would be no cost-of-living package this time appear to have become more equivocal in recent weeks. But giving a lot of money out again through these payments to all households is an inefficient use of State cash. If the Government does not bring this process to an end in the first budget of its new term, then – barring a big squeeze on the State finances – it never will. The plan to increase vital State investment is a key reason why there needs to be some restraint elsewhere. Realistic budgeting for the provision of State services also needs to be restored, ending the annual overruns in areas like health. Relying on corporate tax to keep outperforming as a way to pay for spending coming in ahead of target each year is not a good strategy. The other reason for caution is the uncertainty faced due to the policies of Donald Trump. Despite the trade deal between the EU and US, the economic and political backdrop for Ireland remains risky and unpredictable. Having cash in reserve and pursuing a strategic approach have seldom looked more important.
